Applied Biosystems to invest in VisiGen Biotechnologies Inc.
Applied Biosystems has agreed to invest in, and collaborate with, VisiGen Biotechnologies, Inc. VisiGen's technological approach to DNA sequencing is based on the ability to analyse a single molecule of DNA in real time, which has the potential to drastically reduce the cost of sequencing and significantly improve throughput compared to existing commercially available technologies. Their solution could provide a quantum leap in the scope and scale of research aimed at uncovering the genetic basis of common diseases such as cancer, heart disease and diabetes.
"Applied Biosystems continues to extensively evaluate potential next-generation sequencing technologies. We believe that the quality of VisiGen's science and the progress towards the development of single-molecule sequencing technology is quite impressive," explained Catherine M. Burzik, President of Applied Biosystems.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.